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http://dxObjective: Cardiac surgery patients are treated with antifibrinolytic agents to reduce intra- and postoperative
bleeding. Until 2007, lysine analogues (aminocaproic acid and tranexamic acid) and serine protease inhibitors
(aprotinin) were recommended. In 2008, the U.S. Food and Drug Administration prohibited aprotinin use be-
cause of associated postoperative complications, including cerebrovascular accidents and renal failure. This
work aimed at reevaluating the efficacy and safety of aprotinin versus tranexamic acid in patients undergoing
elective coronary artery bypass surgery.
Methods: Two groups were enrolled in this study. Group A (n ¼ 256), operated from January 2005 to August
2007, was treated with the half-Hammersmith aprotinin regimewhereas group B (n¼ 104), operated after 2008,
was treated with the full-dose tranexamic acid regime. All patients were of low-risk profile, and underwent an
elective, on-pump coronary artery bypass surgery. The main outcome measures were safety, assessed in relation
to thrombosis-related cardiac, cerebral, and renal events; and efficacy, investigated in terms of postoperative
bleeding and infusions of blood products.
Results: Postoperatively, group B demonstrated greater bleeding during the operative and first postoperative
days, and total bleeding (P values  .001); a greater requirement of blood and/or blood products infusions
(P¼ .024); higher postoperative acute renal failure rates (P¼ .028); lower platelet count (P¼ .002); and a higher
postoperative increase in troponin levels (P<.0001).
Conclusions:Among low-risk patients undergoing coronary artery bypass surgery, the half-Hammersmith apro-
tinin-based antifibrinolytic management proved to be more efficacious in terms of bleeding and consumption of
blood products, with no evidence of associated increased rates of postoperative complications. Accordingly, the
usage of aprotinin should be reconsidered for treatment among cohorts of low-risk cardiac patients. (J Thorac
Cardiovasc Surg 2013;145:243-8)P
MCardiac surgery patients are treated routinely with antifibri-
nolytic agents to reduce intra- and postoperative bleeding as
well as infusions of blood products. Until 2007, widespread
use of 2 classes of agents was recommended, both proven to
mitigate bleeding: lysine analogues (aminocaproic acid and
tranexamic acid) and serine protease inhibitors (aprotinin).
Compared with lysine analogues, aprotinin treatment was
associated with an increased risk of mortality and morbid-
ity,1 a finding corroborated by ensuing studies.2 The main
postoperative complications associated with aprotinin use
were reported to include cerebrovascular accidents
(CVAs), renal failure, and reduced graft patency. These
findings led the U.S. Food and Drug Administration
(FDA) to prohibit the use of aprotinin as an antifibrinolytic
agent in 2008.2e Department of Cardiac Surgery, Rambam Health Care Campus, Haifa,
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The Journal of Thoracic and CaThe complications associated with aprotinin in compar-
ison with lysine analogues presumably stemmed from the
postulated propensity of aprotinin to favor thrombosis.3
Aprotinin distinguishes itself from lysine analogues by
its (1) inhibition of soluble proteases (eg, kallikreins, plas-
min, and trypsin), (2) inhibition of activated protein C, (3)
preservation of platelet adhesive and aggregatory proper-
ties, (4) impairment of vascular endothelial cell function
in the coronary and cerebral arteries and aorta, and (5) se-
lective impairment of endothelium-derived relaxation by
dose-dependent inhibition of nitric oxide synthesis and
release.2
Notably, the aforementioned studies on which the FDA’s
recommendation was based enrolled either high-risk pa-
tients with multiple comorbidities1,2 or an assorted cohort
of patients of both low- and high-risk status undergoing
complex cardiac procedures.4 Such heterogeneous recruit-
ment of patients of diverse preoperative risk levels may
have veiled the differential clinical effects of aprotinin in
the management of low- versus high-risk cardiac patients.
The current literature necessitates an assessment of the
effectiveness of aprotinin treatment in a homogenous cohort
of low-risk patients. Such an investigation may indicate an
advantageous treatment regime in a significant fraction of
open-heart cardiac surgery patients.rdiovascular Surgery c Volume 145, Number 1 243
Abbreviations and Acronyms
ACT ¼ activated clotting time
APTT ¼ activated partial thromboplastin time
ARF ¼ acute renal failure
BPT ¼ bypass time
BW ¼ body weight
CABG ¼ coronary artery bypass graft
CCT ¼ crossclamp time
CHF ¼ congestive heart failure
CVA ¼ cerebrovascular accident
FDA ¼ Food and Drug Administration
MI ¼ myocardial infarction
PT ¼ prothrombin time
Perioperative Management Beckerman et al
P
MThe aim of this work was to revisit the relevance of the
aforementioned aprotinin-related studies and FDA recom-
mendations to low-risk cardiac patients. Accordingly, the
current study focused on elective coronary artery bypass
graft (CABG) patients by comparing the consequences of
the half-Hammersmith aprotinin regime and a full-dose tra-
nexamic acid regime in terms of safety and efficacy. Safety
was assessed in relation to thrombosis-related cardiac, cere-
bral, and renal events. Efficacy was investigated in terms of
postoperative bleeding and infusions of blood products.
Because the use of antifibrinolytic agents presents an em-
bedded clinical routine dictated by guidelines,1 conducting
independent, placebo-controlled clinical studies investigat-
ing the safety and efficacy of antifibrinolytic agents be-
comes unfeasible. In addition, regulatory approval for
using these agents differs among countries, thus making
a large-scale, multicountry, comparative study challenging.
Therefore, the current work investigated retrospectively the
study population in 2 different time periods, distinguished
by the governing antifibrinolytic treatment regime.METHODS
Patients
In our institute, all patients routinely received intraoperative aprotinin;
this policy ceased in our institute in January 2008. The current study com-
pared 2 patient groups. The first, designated group A (n ¼ 256), was oper-
ated between January 2005 and August 2007 and received aprotinin. The
second, designated group B (n ¼ 104), was operated between September
2009 and April 2010 and received tranexamic acid. A total of 1134 patients
were operated during both periods, of whom 360 (groups A and B, collec-
tively) were elective patients who underwent on-pump CABG.
The study question focused on a cohort of low-risk patients. Accord-
ingly, inclusion criteria were patients (1) undergoing elective CABG sur-
gery, (2) demonstrating a normative preoperative coagulation profile
(namely, values within the normal range of platelet counts, activated partial
thromboplastin time [APTT], prothrombin time [PT], and international
normalized ratio), (3) with a left ventricular ejection fraction 50%, (4)
with a preoperative creatinine level2 mg/dL; and (5) not on preoperative
clopidogrel or anticoagulation treatment. Aspirin administration was not
discontinued at any point before or after the surgery.244 The Journal of Thoracic and Cardiovascular SurgDeclaration of Helsinki
This study complies with the Declaration of Helsinki and was approved
by a locally appointed ethics committee (0335-10-RMB).
Antifibrinolytic Treatment Protocol
Aprotininwas administered routinely to all patients in groupA according
to the half-Hammersmith regime. Initially, a test dose (10,000 kIU) was
given intravenously. Ten minutes later, the loading dose (1 million kIU)
was administered intravenously over a time period of 20 to 30 minutes. Fi-
nally, the pump primewas given in 2 parts: First, it was added during the re-
circulation of the priming fluid (1 million kIU) and, second, it was given
intravenously as a continuous infusion during operation (250,000kIU/hour).
The tranexamic acid treatment regime in group B was based on the pa-
tient’s body weight. Accordingly, a loading dose was given immediately
before skin cut (calculated as 12.53 Body weight [BW], measured in mil-
ligrams), and afterward a maintenance dose was started and continued until
4 hours postoperatively (calculated as 6.5 3 BW, measured in milligrams
per hour).5
Blood and Blood Products Transfusion Protocol
Packed cells transfusion was indicated for patients in whom hemoglobin
levels were<7 g/dL and for patients in whom the hemoglobin level was
between 7 g/dL and 8 g/dL and were symptomatic (demonstrated
clinical signs of hypovolemia and anemia). Fresh-frozen plasma and plate-
let infusions were given only in cases of excessive postoperative bleeding
(ie,>200 mL/hour or>100 mL/hour after the first hour with normal acti-
vated clotting time [ACT] orAPTT). Fresh-frozen plasmawas administered
in case of abnormal PT, only after correction of APTT by protamine infu-
sions. Platelets were administered after correcting both APTT and PT if
excessive bleeding continued, regardless of the platelet count.
Statistical Analysis
All analyses were conducted using SPSS version 19 (SAS Institute, Inc,
Cary, NC). The study outcome measures were stratified into 3 levels: pre-,
intra-, and postoperative parameters. Preoperatively, relevant operative risk
factors, demographic variables, and baseline illnesses were documented.
Intraoperatively, factors that are known to influence postoperative bleeding
were collected and compared—namely, cross-clamp time (CCT), bypass
time (BPT), minimal operative temperature, and last operative ACT. In ad-
dition, the intraoperative usage of blood product infusion was compared.
Postoperatively, total bleeding amount and infusion of blood products
were compared. Themain outcomemeasures of the current studywere post-
operative platelet count, acute renal failure (ARF), CVA, acute myocardial
infarction (MI), and 30-day mortality. Acute renal failure was defined as an
elevation of the preoperative creatinine level to>1.5 times the baseline or
the need for dialysis. Acute MI was diagnosed as troponin elevation>4
times the upper limit of the normal range. The TROPONIN-I test was per-
formed in all cases (normal range: 0-0.028 ng/mL). Total bleeding
was calculated as the sum of the average bleeding on the operative day be-
tween the patients operated during the morning and afternoon hours, post-
operative day 1, and postoperative day 2. Because of data availability,
comparison of troponin values was performed among 144 patients in the
aprotinin-treated group and 121 patients in the tranexamic acid-treated
group. Continuous variables are presented as mean  standard deviation.
Unpaired t tests were used to compare the means of continuous variables
between groupAand groupB.Mann-WhitneyU testswere used to compare
data of nonnormal distribution, which are described by their median and in-
terquartile range (25%-75%). Statistical significance was set at P<.05.RESULTS
The groups were comparable demographically and had
the same mean age of 64  10 years. The male-to-femaleery c January 2013
TABLE 1. Demographics and past diagnoses
Parameter
Group A
(aprotinin;
n ¼ 256)
Group B
(tranexamic acid;
n ¼ 104)
P
value
Demographics
Male-to-female ratio (%) 199:57 (78:22) 80:24 (77:23) NS
Age, n  SD 64  10 64  10 NS
Past diagnoses, n (%)
Ischemic heart disease 193 (75) 72 (69) NS
Smokers 106 (41) 39 (38) NS
Hyperlipidemia 200 (78) 85 (82) NS
Hypertension 186 (73) 75 (72) NS
Diabetes mellitus 99 (39) 49 (47) NS
Renal failure 12 (5) 10 (10) NS
Peripheral vascular disease 22 (9) 11 (11) NS
Congestive heart failure 9 (4) 14 (14) .001
Cerebrovascular accident 10 (4) 11 (11) .023
Chronic obstructive
pulmonary disease
12 (5) 6 (6) NS
Obesity 26 (10) 12 (12) NS
Atrial fibrillation 14 (6) 7 (7) NS
NS, Not significant; SD, standard deviation.
TABLE 2. Operative parameters
Parameter
Group A
(aprotinin)
Group B
(tranexamic acid)
P
value
Cross clamp time, min;
mean  SD
69  21 73  28 NS
Bypass time, min;
mean  SD
116  31 107  39 NS
Minimal temperature,
C; mean  SD
33  2 33  1 NS
Activated clotting time,
min; mean  SD
130  44 130  13 NS
Balance, mL; mean
(range)
2414 (1036-3097) 2631 (1633-3427) NS
Packed cells, mL; mean
(range)
371 (96-591) 421 (113-612) NS
Packed cells, n (%) 71 (28) 42 (40) 0.024
Platelet infusion, n (%) 4 (1.6) 3 (2.9) NS
Fresh-frozen plasma,
n (%)
3 (1) 7 (7) 0.008
SD, Standard deviation; NS, not significant.
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Mratio was also comparable between the 2 groups, with 78%
men and 22% women in group A, and 77% men and 23%
women in group B.
The 2 groups differed in relation to their baseline mean
hemoglobin levels: 14  2.5 g/dL in the aprotinin group
and 13.4 1.8 g/dL in the tranexamic acid group (P¼ .03).
Table 1 presents preoperative variables and diagnoses
prior to the CABG surgery. The groups were comparable
with regard to prior diagnoses of ischemic heart disease,
smoking, hyperlipidemia, hypertension, diabetes mellitus
type 2, renal failure, chronic obstructive pulmonary disease,
obesity, and previous history of atrial fibrillation, either par-
oxysmal or chronic. However, the groups differed with re-
gard to previous history of congestive heart failure and
previous CVAs, which were more prevalent in group B.
Table 2 delineates the operative parameters that have an
influence on the homeostatic system and postoperative
bleeding—namely, CCT, BPT, minimal operative tempera-
ture, and last ACT. No differences were found in these pa-
rameters between the 2 groups examined. No significant
differences were observed between groups A and B in terms
of the end operative fluid balance, packed cells infusions,
and platelets transfusion. Packed cells were infused to 71
patients (28%) in group A versus 42 patients (40%) in
group B (P ¼ .024). Fresh-frozen plasma was infused to 3
patients (1%) in group A versus 7 patients (7%) in group
B (P ¼ .008).
The postoperative parameters and primary end points of
the current study are compared in Table 3. Greater postop-
erative bleeding was observed in the tranexamic acid-
treated group during the operative and first postoperative
days (P values  .001). In keeping, the total postoperativeThe Journal of Thoracic and Cableeding was greater in the tranexamic acid-treated group
(P < .0001). A greater proportion of tranexamic acid-
treated patients required blood and/or blood product infu-
sions (P ¼ .024).
In the tranexamic acid-treated group, more events of
postoperative ARF were observed (P ¼ .028), as well as
a lower platelet count (P¼ .002) and a higher postoperative
increase in troponin levels (P<.0001).
DISCUSSION
The main finding of the current study is that, among low-
risk patients undergoing CABG, the half-Hammersmith
aprotinin-based antifibrinolytic management resulted in
lower bleeding rates during the operative and the first post-
operative day, and decreased blood product infusions com-
pared with the full-dose tranexamic acid treatment
management. Regarding postoperative complications, the
aprotinin-treated group demonstrated lower rates of ARF,
decreased troponin levels, and higher platelet counts. The
aprotinin- and tranexamic acid-based treatment regimes
yielded comparable postoperative CVAs and 30-daymortal-
ity rates (Table 3).
Bleeding and Infusion of Blood Products
In relation to the baseline characteristics of the patients,
as discussed previously, none received antiplatelet treat-
ment (except for aspirin, which was used routinely). Never-
theless, the baseline hemoglobin level differed between the
groups. Although statistically significant, this result has
limited clinical relevance because of the minor difference
in mean hemoglobin values and comparable confidence
intervals.
In terms of efficacy—namely, reduction of blood loss and
the proportion of transfused patients—current findingsrdiovascular Surgery c Volume 145, Number 1 245
TABLE 3. Postoperative bleeding, transfusion, and postoperative complications
Parameter Group A (aprotinin) Group B (tranexamic acid) P value
Postoperative bleeding, median (interquartile 25% and 75% range)
Morning operations, mL 300 (210-440) 465 (331-790) .001
Afternoon operations, mL 250 (150-380) 415 (250-580) .0001
Bleeding, mL, POD1 270 (190-390) 440 (300-690) .0001
Bleeding, mL, POD2 90 (50-248.75) 160 (65-285) NS
Total bleeding 869 1347 <.0001
Blood products
Packed cells, n transfused patients (%) 71 (28) 42 (40) .024
Packed cells, mean transfused volume  SD 380  206 440  264 NS
Platelets, n (%) 4 (1.6) 3 (2.9) NS
Fresh-frozen plasma, n (%) 3 (1.2) 7 (6.7) .008
Morbidity and mortality
Reoperation, n (%; range) 4 (1.6; 0.006-0.04) 2 (1.9; 0.006-0.07) NS
Cerebrovascular accident, n (%; range) 1 (0.4; 0.0009-0.02) 1 (1; 0.002-0.05) NS
Cardiogenic shock, n (%; range) 4 (1.6; 0.006-0.04) 3 (2.9; 0.01-0.08) NS
Acute pulmonary edema, n (%; range) 12 (4.7; 0.03-0.08) 2 (1.9; 0.006-0.07) NS
Septic shock, n (%; range) 4 (1.6; 0.06-0.04) 2 (1.90.006-0.07) NS
Acute renal failure, n (%; range) 14 (5.5; 0.03-0.09) 13 (12.5; 0.07-0.2) .028
Platelet count, minimum (range) 143 (113.7-176) 123 (100-149) .002
Troponin, POD1; mean (range) 2.3 (0.9-5.1) 6.6 (5.9-11.4) <.0001
Troponin, maximum postoperative; mean (range) 2.9 (0.7-5.5) 8.4 (6.9-12.9) <.0001
30-Day mortality, n (%; range) 5 (1.9; 0.009-0.04) 4 (3.8; 0.02-0.09) NS
POD, Postoperative day; NS, not significant; SD, standard deviation.
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Mdemonstrate that aprotinin is more effective than tranexamic
acid. These findings are in line with previous reports, en-
compassing 17 randomized controlled trials of approxi-
mately 5000 patients that compared treatment with the
full-Hammersmith dose of aprotinin with tranexamic
acid.1,6-21 Of these studies, 5 indicated aprotinin as the
most effective in terms of reduction of blood loss
and transfusion requirements,6,10,14,18,22 whereas none
identified tranexamic acid as such. Wang and colleagues22
investigated patients who underwent isolated CABG and
concluded that, compared with the 981 control patients
who received no aprotinin, the 4122 patients treated with
the full-Hammersmith aprotinin regimen demonstrated sig-
nificantly reduced blood loss. The current study contributes
to this line of findings by documenting a similar efficacy us-
ing the half-Hammersmith regime of aprotinin. This follows
the lines of previous studies23,24 that reported that,
compared with control patients who received no aprotinin,
patients treated perioperatively with low-dose aprotinin
demonstrated a reduced risk of peri- and postoperative use
of packed red blood cells and decreased postoperative blood
loss. Stressing the potential efficacy of aprotinin in blood
loss reduction, Maddali and associates25 reported that, com-
pared with the half-Hammersmith regimen, a microdose
was more effective in reducing postoperative blood loss
and blood transfusion. An additional efficacy-related attri-
bute of the aprotinin-treated group in the current study
was their comparable requirement of reexploration com-
pared with the tranexamic acid-treated group.246 The Journal of Thoracic and Cardiovascular SurgMortality
In terms of mortality, no significant difference was found
in 30-daymortality rates between the groups treated with the
half-Hammersmith aprotinin dose and tranexamic acid. The
documented increased risk of death associatedwith aprotinin
in recent trials, including the BART trial by Fergusson and
colleagues,1 which compared the effect of aprotinin with
that of tranexamic acid, was shown either in patients under-
going high-risk cardiac surgery or in mixed groups undergo-
ing both high- and low-risk cardiac surgery. Fergusson and
colleagues1 reported a relative 30-day mortality risk of
1.55 (95% confidence interval, 1.06-2.22) in the aprotinin
group compared with tranexamic acid-treated patients. The
investigators concluded that aprotinin should no longer be
used in high-risk cardiac surgery. These recommendations
address a cohort of distinctive characteristics, including
older age, higher incidence of poor or moderate left ventric-
ular function, and a need for urgent surgery. Furthermore, the
BART trial included patients with higher incidence of body
mass and diabetes mellitus, history of thromboembolism,
and preoperative chronic renal dysfunction. In the same
vein, a portion of these patients underwent surgery of the
ascending aorta or aortic arch. Importantly, no study,
including the current one, has reported a higher mortality
risk associated with aprotinin among low-risk patients.
Morbidity
With regard to morbidity, the most widely reported
postoperative aprotinin-related complications includeery c January 2013
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MARF, graft occlusion (ie postoperative MI), and
CVA.1,2 Compared with the tranexamic acid, the half-
Hammersmith aprotinin-treated group of the current study
demonstrated lower ARF incidence, lower troponin levels,
and comparable CVA rates. In addition, the aprotinin-
treated group demonstrated a lower incidence of thrombocy-
topenia. Because the previously mentioned complications
are suspected to be related to a state of increased or unop-
posed thrombosis, and are increased with the full-
Hammersmith aprotinin regime, it may be postulated that
the lower rate ofmajor complications observed in the current
study is associated with the implementation of the half-
Hammersmith aprotinin regime. The current complication
event rates and the matching 95% confidence intervals are
smaller than in corresponding studies that focused on
high-risk patients, and are comparable with investigations
of patients with similar preoperative risks.1,6 Notably, the
higher troponin levels in the tranexamic acid group of the
current study were not associated with relevant clinical
findings.
Sander and associates26 demonstrated that the routine use
of tranexamic acid did not result in a decreased relative risk
for the development of postoperative neurologic dysfunc-
tion and/or renal injury compared with aprotinin among
a cohort of low-risk patients. In the aforementioned study
by Wang and colleagues,22 aprotinin use was associated
with neither major complications nor with long-term major
adverse cardiac or cerebrovascular events. Examining
a group of low-risk patients, Dietrich and associates27 also
demonstrated no association between aprotinin, adminis-
tered according to the full-Hammersmith protocol, and an
increased risk for postoperative complications (ie, renal
failure and MI, as well as mortality).
It is noteworthy that the investigated thrombosis-related
complications were increased in the tranexamic acid-
treated group. A possible explanation for this finding may
be delineated by Terrell and colleagues,28 who studied the
effect of aprotinin and tranexamic acid on thrombosis and
fibrinolysis in a model of cardiopulmonary bypass in
dogs. In the aprotinin-treated group, the presence of heparin
was associated with reduction in blood loss, but also with
diminished filter deposits.28 This counterbalancing effect
of thrombosis and fibrinolysis seen with aprotinin could
not be observed with tranexamic acid. Tranexamic acid di-
minishes bleeding, but the thrombus formation during con-
tact activation is augmented. It is postulated that the sole
inhibition of the fibrinolytic system by tranexamic acid,
with no anticoagulant/antithrombotic activity, may advance
unsuitable thrombus development.29
Comparing the adverse event rates of the current study
with those reported by Fergusson and colleauges1 indicates
that CVA, cardiogenic shock, and ARF were less prevalent
in our sample (CVA: 0.4% vs 2.9% and 1% vs 3.7% in the
aprotinin and tranexamic acid groups, respectively;The Journal of Thoracic and Cacardiogenic shock: 1.6% vs 14.5% and 2.9% vs 14.6%
in the aprotinin and tranexamic acid groups, respectively;
ARF: 5.5% vs 13.2% and 12.5 vs 12.7% in the aprotinin
and tranexamic acid groups, respectively). It should be
noted that the patients of the current study were low-risk pa-
tients treated with the half-Hammersmith aprotinin dose
compared with the high-risk patients treated with the full-
Hammersmith regime in the BART study.
Study Limitations
Several limitations in the current study are to be addressed.
First, the present report is of a retrospective design; however,
such a design is the only feasible one, considering the FDA
constraints associated with the current study question. Sec-
ond, the aprotinin-treated groupdemonstrated preoperatively
lower CVA and congestive heart failure (CHF) rates, which
may resemble a lower risk patient population. Regarding
the former complication, it developed postoperatively in
only 1 patient in either group. Therefore, it would be safe
to assume that preoperative and postoperative CVA rates
are independent. Furthermore, neither group demonstrated
neurologic dysfunction preoperatively, which may have per-
tained to a minor, resolved CVA. The difference in CHFmay
have been derived from the various approaches of the clini-
cians regarding its determination and the retrospective design
of the current study. The difference in CHF rates probably
had no impact on the study outcomes, because patients
with a reduced left ventricular ejection fraction, based on ei-
ther echocardiography or ventriculography, were excluded;
thus, preoperative CHF was probably a result of diastolic
dysfunction. Third, a comparison of the half- and full-
Hammersmith regimes could have yielded more informative
results. Last, although themajor operativevariables known to
influence postoperative bleeding were comparable in both
groups (BPT, CCT, and minimal operative temperature), ad-
ditional operative factors may have been left unaddressed.
CONCLUSIONS
Among low-risk patients undergoing CABG, half-
Hammersmith aprotinin-based antifibrinolytic management
proved to be more efficacious in terms of bleeding and in-
fusion of blood products, with no evidence of associated in-
creased rates of postoperative complications. Accordingly,
the usage of aprotinin should be reconsidered for treatment
in cohorts of low-risk cardiac patients.
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